about
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive EsophagitisThe Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver TransplantationThe Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction CarcinomaMulti-center Observation of the Natural Course of Inherited Retinal DystrophiesArtificial Intelligence-assisted Glaucoma Screening (AIAGS)The CHINA TFNA StudyStudy of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's DiseaseCompare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for HypertensionNeo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal CancerStudy of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure PatientsA Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerEfficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With HyperlipidemiaA Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMDAntifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCTNimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaA Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular EdemaA Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal CancerA Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular DegenerationA Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomySafety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerHigh Dose PET/CT-guided Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Non-small Cell Lung CancerA Study of Abemaciclib (LY2835219) in Participants With Breast CancerLow Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCTAnti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL
P6153
Q57110017-160D5C9C-3D3F-49C6-B3A9-70A2BFBB5734Q57955790-F00408EA-D6F7-483C-B79A-B7F78ED69AB0Q63448431-19F92024-A4BA-4E5B-81D6-9C9385BF5049Q80202007-BAE60333-C5AF-4CFF-874D-044EE494E1A4Q81045132-04D38819-E753-4824-A149-677C4D5E11A7Q85888858-D37E567F-F39E-4798-9A47-EEC26B187427Q85997586-9DD8253F-98E5-4F33-8AE2-A805904217CAQ87641289-AD2BDF5C-980A-43AB-9F5B-E7A3237AFAD2Q87838067-175404C3-026D-4E60-B481-DABE1F7DFB0BQ87885874-F939C077-FDE3-41AB-A0D1-E050783D2CC2Q88455790-8249A856-18D3-47AC-9530-85EC26FF357BQ89071089-CC7E1487-34FF-48DE-BF36-8E10A7CA933D
P108
Q61727955-96C3ABBE-DBA2-43E1-ACAF-5ACFBDD69A3EQ61904907-97E524F3-6BE3-4FCD-AA55-98DF2BC172CEQ61909323-E3A3C475-CB13-4510-855A-8B406F087E7BQ61938480-E883C8FB-E80B-4C2C-9B14-6F940B11A5BCQ61974963-28B1BB59-DFB8-4B8A-BFD1-4BBF0E9AAFB3Q62030726-453DCC85-3227-45B5-BAD3-21AA81E29B6DQ62054101-19011CA9-F536-45D4-9959-476C3CE9A1E7Q62054791-DFA20C3C-F810-4A14-B579-2EF9379A4EC1Q62063070-A6AD801B-15B4-4C3E-9E88-7C52B07AAB4BQ63317221-9EAB4B2F-0A37-4E62-925B-1FF744B211EEQ63320448-0BD0A800-DE4F-473B-8007-7CD07D32ECB6Q63322538-41E37764-71A1-4A63-84F7-7A47B8A5CD36Q63322622-9BD4BBDF-67C7-4059-9138-D0E53E496AD3Q63335890-ED9043E2-F8F9-44EC-8914-9B6C1BFCB0F4Q63338830-EBF984D0-1DB5-462A-B80E-3D43CD5FF150Q63340147-41FEC17F-D4B2-4202-98E6-079506528C16Q63340997-1A36EB50-A920-4480-BD44-C157D807DDA1Q63341008-9DFB169B-1C4A-4496-AF4E-EC92141ED4B9Q63393863-D5CD7872-A12A-460D-88CC-DB31418F4259Q63397199-ED299138-1ADD-4A5F-9B07-91D3A1F65EB8Q63405688-98F30D32-0C0C-44E7-AF2D-9720EEA0AC5BQ63572977-2109AF42-868B-4C54-8E77-580A25E8C5F9Q63575010-0D531516-1D6A-4AC7-BC08-5DCF7E3E332BQ63575030-EF0ABEEA-F6A7-4C54-9E80-08F80E1AE639Q64172708-8844437A-2FBC-4427-995D-FF65ACF99601Q64173553-27D3EEBE-234A-4319-AED6-FCD009E82CF0Q64184819-432619AA-A59F-4A13-A1EC-3CD0A68DCDDC
P6153
description
griya sakit
@jv
healthcare organization in Shanghai, China
@en
rumah sakik
@min
rumah sakit di Republik Rakyat Tiongkok
@id
rumoh sakét
@ace
مستشفى في شانغهاي، الصين
@ar
name
Shanghai First People's Hospital
@en
type
label
Shanghai First People's Hospital
@en
altLabel
Shanghai General Hospital
@en
prefLabel
Shanghai First People's Hospital
@en
P131
P213
0000 0004 1760 4628
P2427
grid.412478.c
P3500
P571
1864-01-01T00:00:00Z
P625
Point (121.488545 31.253295)